Table 2. Univariate and multivariate Cox proportional hazard analysis of disease-free survival and overall survival.
| Variable | Totaln | DFS | OS | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | ||||||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age | 0.249 | 0.262 | 0.152 | 0.100 | |||||
| < 60 | 38 | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | ||||
| ≥ 60 | 77 | 1.42 (0.78–2.57) | 1.40 (0.77–2.57) | 1.65 (0.83–3.26) | 1.78 (0.90–3.54) | ||||
| Sex | 0.396 | 0.958 | |||||||
| Male | 52 | 1.00 (Reference) | 1.00 (Reference) | ||||||
| Female | 63 | 1.26 (0.74–2.12) | 0.98 (0.55–1.77) | ||||||
| Location | 0.948 | 0.449 | |||||||
| Proximal | 58 | 1.00 (Reference) | 1.00 (Reference) | ||||||
| Distal | 57 | 1.02 (0.60–1.72) | 0.80 (0.44–1.43) | ||||||
| Lymph nodes examined | 0.177 | 0.108 | 0.590 | ||||||
| ≥ 12 | 80 | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | |||||
| < 12 | 35 | 1.46 (0.84–2.52) | 1.61 (0.90–2.88) | 1.19 (0.64–2.20) | |||||
| Differentiation | 0.415 | 0.670 | |||||||
| Well to moderate | 95 | 1.00 (Reference) | 1.00 (Reference) | ||||||
| Poor | 20 | 0.73 (0.35–1.55) | 0.84 (0.37–1.88) | ||||||
| pT4 | 0.262 | 0.456 | 0.378 | ||||||
| No | 103 | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | |||||
| Yes | 12 | 0.56 (0.20–1.55) | 0.67 (0.23–1.92) | 0.63 (0.23–1.76) | |||||
| Lymphovascular invasion | 0.101 | 0.193 | 0.047 | 0.200 | |||||
| No | 95 | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | ||||
| Yes | 20 | 1.76(0.90–3.44) | 1.64 (0.78–3.43) | 2.13 (1.01–4.52) | 1.73 (0.75–3.99) | ||||
| Mucin production | 0.422 | 0.466 | |||||||
| No | 94 | 1.00 (Reference) | 1.00 (Reference) | ||||||
| Yes | 21 | 1.29 (0.69–2.41) | 1.29 (0.65–2.56) | ||||||
| KRAS | 0.524 | 0.708 | |||||||
| Wild type | 75 | 1.00 (Reference) | 1.00 (Reference) | ||||||
| Mutant | 40 | 1.20 (0.69–2.07) | 1.13 (0.61–2.08) | ||||||
| MSI status | 0.470 | 0.419 | |||||||
| MSS+MSI-low | 59 | 1.00 (Reference) | 1.00 (Reference) | ||||||
| MSI-high | 56 | 0.82 (0.48–1.40) | 0.78 (0.43–1.42) | ||||||
| CIMP/MLH1 | 0.002 | 0.011 | 0.000 | 0.002 | |||||
| Others | 106 | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | ||||
| CIMP+/MLH1-U | 9 | 3.59 (1.59–8.08) | 3.16 (1.30–7.64) | 5.49 (2.21–13.62) | 4.70 (1.74–12.72) | ||||
Abbreviations: DFS, disease-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; CIMP, CpG island methylator phenotype; MLH1-M, MLH1-methylated; MLH1-U, MLH1-unmethylated; MSS, microsatellite stable; MSI, microsatellite instability. A backward elimination with threshold of P = 0.300 was used to select variables in the final models.